![](/img/cover-not-exists.png)
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
Plummer, Ruth, Stephens, Peter, Aissat-Daudigny, Louiza, Cambois, Anne, Moachon, Gilbert, Brown, Peter D., Campone, MarioVolume:
74
Language:
english
Journal:
Cancer Chemotherapy and Pharmacology
DOI:
10.1007/s00280-014-2486-9
Date:
August, 2014
File:
PDF, 363 KB
english, 2014